Accuracy of methionine-PET in predicting the efficacy of heavy-particle therapy on primary adenoid cystic carcinomas of the head and neck

Radiation Oncology

Tadashi Kamada¹  Tsuneo Saga¹  Koji Kawaguchi²  Azusa Hasegawa¹  Katsuyuki Tanimoto¹  Seiya Ohashi²  Kyosan Yoshikawa¹  Sachiko Toubaru² 

[1] Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan;Oral and Maxillofacial Surgery, Tsurumi University School of Dental Medicine, 2-1-3 Tsurumi, Tsurumi-ku, Yokohama 230-8501, Japan

关键词: Multivariate analysis;    Univariate analysis;    Head and neck adenoid cystic carcinoma;    Carbon ion radiotherapy;    C-11-Methionine PET;   

Others  :  1153767
DOI  :  10.1186/1748-717X-8-143

 received in 2012-12-10, accepted in 2013-06-04,  发布年份 2013

【 摘 要 】

Background

We evaluated whether or not PET or PET/CT using L-methyl-[11C]-methionine (MET) can allow for the early prediction of local recurrence and metastasis, as well as the prognosis (disease-specific survival), in patients with adenoid cystic carcinoma of the head and neck treated by carbon ion beam radiotherapy.

Methods

This was a retrospective cohort study of sixty-seven patients who underwent a MET-PET or PET/CT study prior to and one month after the completion of carbon ion radiotherapy (CIRT). The minimum follow-up period for survivors was 12 months. The MET accumulation of the tumor was evaluated using the semiquantitative tumor to normal tissue ratio (TNR). A univariate analysis was conducted using the log-rank method, and the Cox model was used in a multivariate survival regression analysis.

Results

The average TNR prior to and following treatment was 4.8 (±1.5) and 3.0 (±1.3), respectively, showing a significant decrease following treatment. In the univariate analysis, a high TNR prior to treatment (TNRpre) was a significant factor for predicting the occurrence of metastasis and the disease-specific survival. A high TNR following treatment (TNRpost) was a significant factor for predicting the development of local recurrence. The residual ratio of TNR changes (TNRratio) seemed to be less useful than the TNRpre. In the multivariate analysis, the TNRpost and tumor size were the factors found to significantly influence the risk of local recurrence. The TNRpre, TNRratio and tumor size were all significant factors influencing the occurrence of metastasis. Regarding the disease-specific survival, the TNRpre and age were the only factors with a significant influence on the outcome.

Conclusions

The TNRpre was a factor that was significantly related to the occurrence of metastasis and the disease-specific survival after CIRT for adenoid cystic carcinoma of the head and neck. The TNRpost was a factor that was significantly related to the development of local recurrence. Thus, MET-PET or PET/CT can be useful for predicting or determining the therapeutic efficacy of CIRT.

【 授权许可】

   
2013 Toubaru et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Spiro RH, Huvos AG, Strong EW: Adenoid cystic carcinoma of salivary origin. A clinicopathologic study of 242 cases. Am J Surg 1974, 128(4):512-520.
• [2]Kim KH, Sung MW, Chung PS, Rhee CS, Park CI, Kim WH: Adenoid cystic carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 1994, 120(7):721-726.
• [3]Khan AJ, DiGiovanna MP, Ross DA, Sasaki CT, Carter D, Son YH, et al.: Adenoid cystic carcinoma: a retrospective clinical review. Int J Cancer 2001, 96(3):149-158.
• [4]Takagi D, Fukuda S, Furuta Y, Yagi K, Homma A, Nagahashi T, et al.: Clinical study of adenoid cystic carcinoma of the head and neck. Auris Nasus Larynx 2001, 28:S99-S102.
• [5]Spiro RH: Distant metastasis in adenoid cystic carcinoma of salivary origin. Am J Surg 1997, 174(5):495-498.
• [6]Kokemueller H, Eckardt A, Brachvogel P, Hausamen JE: Adenoid cystic carcinoma of the head and neck-a 20 years experience. Int J Oral Maxillofac Surg 2004, 33(1):25-31.
• [7]Mendenhall WM, Morris CG, Amdur RJ, Werning JW, Hinerman RW, Villaret DB: Radiotherapy alone or combined with surgery for adenoid cystic carcinoma of the head and neck. Head Neck 2004, 26(2):154-162.
• [8]Dodd RL, Slevin NJ: Salivary gland adenoid cystic carcinoma: a review of chemotherapy and molecular therapies. Oral Oncol 2006, 42(8):759-769.
• [9]Blakely EA: Cell inactivation by heavy charged particles. Radiat Environ Biophys 1992, 31(3):181-196.
• [10]Tobias CA, Blakely EA, Alpen EL, Castro JR, Ainsworth EJ, Curtis SB, et al.: Molecular and cellular radiobiology of heavy ions. Int J Radiat Oncol Biol Phys 1982, 8(12):2109-2120.
• [11]Ando K, Koike S, Ohira C, Chen YJ, Nojima K, Ando S, et al.: Accelerated reoxygenation of a murine fibrosarcoma after carbon-ion radiation. Int J Radiat Biol 1999, 75(4):505-512.
• [12]Kanai T, Endo M, Minohara S, Miyahara N, Koyama-ito H, Tomura H, et al.: Biophysical characteristics of HIMAC clinical irradiation system for heavy-ion radiation therapy. Int J Radiat Oncol Biol Phys 1999, 44(1):201-210.
• [13]Hoffman RM: Altered methionine metabolism. DNA methylation and oncogene expression in carcinogenesis. A review and synthesis. Biochim Biophys Acta 1984, 738(1–2):49-87.
• [14]Hoffman RM: Unbalanced transmethylation and the perturbation of the differentiated state leading to cancer. Bioessays 1990, 12(4):163-166.
• [15]Stern PH, Hoffman RM: Elevated overall rates of transmethylation in cell lines from diverse human tumors. In Vitro 1984, 20(8):663-670.
• [16]Stern PH, Wallace CD, Hoffman RM: Altered methionine metabolism occurs in all members of a set of diverse human tumor cell lines. J Cell Physiol 1984, 119(1):29-34.
• [17]Wheatley DN: On the problem of linear incorporation of amino acids into cell protein. Experientia 1982, 38(7):818-820.
• [18]Mizoe JE, Tsujii H, Kamada T, Matsuoka Y, Tsuji H, Osaka Y, et al.: Dose escalation study of carbon ion radiotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2004, 60(2):358-364.
• [19]Tsujii H, Mizoe JE, Kamada T, Baba M, Tsuji H, Kato H, et al.: Clinical results of carbon ion radiotherapy at NIRS. J Radiat Res 2007, 48(Suppl A):A1-A13.
• [20]Okada T, Kamada T, Tsuji H, Mizoe JE, Baba M, Kato S, et al.: Carbon ion radiotherapy: clinical experiences at National Institute of Radiological Science (NIRS). J Radiat Res 2010, 51(4):355-364.
• [21]Zhang H, Yoshikawa K, Tamura K, Tomemori T, Sagou K, Tian M, et al.: (11)C]methionine positron emission tomography and survival in patients with bone and soft tissue sarcomas treated by carbon ion radiotherapy. Clin Cancer Res 2004, 10(5):1764-1772.
• [22]Koizumi M, Saga T, Yoshikawa K, Suzuki K, Yamada S, Hasebe M, et al.: C-11-methionine-PET for evaluation of carbon ion radiotherapy in patients with pelvic recurrence of rectal cancer. Mol Imaging Biol 2008, 10(6):374-380.
• [23]Tamura K, Yoshikawa K, Ishikawa H, Hasebe M, Tsuji H, Yanagi T, et al.: Carbon-11-methionine PET imaging of choroidal melanoma and the time course after carbon ion beam radiotherapy. Anticancer Res 2009, 29(5):1507-1514.
• [24]Hasebe M, Yoshikawa K, Ohashi S, Toubaru S, Kawaguchi K, Sato J, et al.: A study on the prognostic evaluation of carbon ion radiotherapy for head and neck adenocarcinoma with C-11 methionine PET. Mol Imaging Biol 2010, 12(5):554-562.
• [25]Hermanek P, Sobin LH, International Union Against Cancer: TNM classification of malignant tumors: fourth, fully revised edition. Geneva: Published by International Union Against Cancer; 1987:13-35.
• [26]World Health Organization: WHO Handbook for Reporting the Results of Cancer Treatment, Definitions of objective response. Geneva: World Health Organization; 1979:23-25. 48
• [27]Långström B, Antoni G, Gullberg P, Halldin C, Malmborg P, Någren K, et al.: Synthesis of L- and D-[methyl-11C]methionine. J Nucl Med 1987, 28(6):1037-1040.
• [28]Zhang H, Yoshikawa K, Tamura K, Sagou K, Tian M, Suhara T, et al.: Carbon-11-methionine positron emission tomography imaging of chordoma. Skeletal Radiol 2004, 33(9):524-530.
• [29]Fiorino C, Sanguineti G, Cozzarini C, Fellin G, Foppiano F, Menegotti L, et al.: Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer. Int J Radiat Oncol Biol Phys 2003, 57(4):953-962.
• [30]Landau S, Rabe-Hesketh S: StatView for windows, version 5.0. Stat Methods Med Res 1999, 8(4):337-341.
• [31]Ganly I, Patel SG, Coleman M, Ghossein R, Carlson D, Shah JP: Malignant minor salivary gland tumors of the larynx. Arch Otolaryngol Head Neck Surg 2006, 132(7):767-770.
• [32]Fordice J, Kershaw C, El-Naggar A, Goepfert H: Adenoid cystic carcinoma of the head and neck: predictors of morbidity and mortality. Arch Otolaryngol Head Neck Surg 1999, 125(2):149-152.
• [33]Lindholm P, Leskinen-Kallio S, Grénman R, Lehikoinen P, Någren K, Teräs M, et al.: Evaluation of response to radiotherapy in head and neck cancer by positron emission tomography and [11C]methionine. Int J Radiat Oncol Biol Phys 1995, 32(3):787-794.
• [34]Chesnay E, Babin E, Constans JM, Agostini D, Bequignon A, Regeasse A, et al.: Early response to chemotherapy in hypopharyngeal cancer: assessment with (11)C-methionine PET, correlation with morphologic response, and clinical outcome. J Nucl Med 2003, 44(4):526-532.
• [35]Jones AS, Hamilton JW, Rowley H, Husband D, Helliwell TR: Adenoid cystic carcinoma of the head and neck. Clin Otolaryngol Allied Sci 1997, 22(5):434-443.